The boom of Viagra initially ignited significant progress in the medicinal sector, generating a image of guaranteed returns. However, placing capital in companies heavily reliant on blockbuster drugs like the erectile dysfunction pill presents significant dangers. Intellectual property end has led off-brand challenge, reducing revenue share and lik

The recent surge in funding into boutique pharmaceutical companies, particularly those focusing on novel therapies and difficult drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the potential for revolutionary treatments and significant returns is undeniable, the linked risks are also significant. Many of